QualityStocksNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Reduces Debt, Restructures Balance Sheet

Endonovo Therapeutics (OTCQB: ENDV) today announced the reduction of current liabilities and restructuring of the balance sheet through the approved modification of the terms of the Preferred C shares. “Strengthening our balance sheet is a priority we feel is instrumental in our continued and long-term success. This reduction of debt provides us the flexibility to expand our sales and marketing initiatives and to further develop our nationwide reach to hospitals and other medical facilities we have identified as prospective partners without having financial restraints,” Endonovo Therapeutics CEO Alan Collier said in the news release. “Additionally, reducing the debt increases our shareholder equity which is another step towards our goal of attaining Nasdaq listing requirements as we look to uplist. Positioning our company by restructuring and reducing debt will allow us to be in a better position to grow rapidly and capitalize on the increased market growth we are experiencing and will continue to experience.”

To view the full press release, visit http://ibn.fm/i33Js

About Endonovo Therapeutics

Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals(R) therapeutic devices. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals(R) therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (“CNS”) disorders, including traumatic brain injury (“TBI”), acute concussions, post-concussion syndrome and multiple sclerosis. The Company’s noninvasive Electroceutical(R) therapeutic device, SofPulse(R), which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema and has CMS national coverage for the treatment of chronic wounds. The Company’s current portfolio of preclinical-stage Electroceuticals(R) therapeutic devices addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”), and ischemic stroke. The Company’s noninvasive, wearable Electroceuticals(R) therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. For more information, visit www.Endonovo.com.

NOTE TO INVESTORS: The latest news and updates relating to ENDVD are available in the company’s newsroom at http://ibn.fm/ENDV

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php